AU2013232733B2 - Method for treating inflammation - Google Patents

Method for treating inflammation Download PDF

Info

Publication number
AU2013232733B2
AU2013232733B2 AU2013232733A AU2013232733A AU2013232733B2 AU 2013232733 B2 AU2013232733 B2 AU 2013232733B2 AU 2013232733 A AU2013232733 A AU 2013232733A AU 2013232733 A AU2013232733 A AU 2013232733A AU 2013232733 B2 AU2013232733 B2 AU 2013232733B2
Authority
AU
Australia
Prior art keywords
tmp
disease
subject
inflammation
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013232733A
Other languages
English (en)
Other versions
AU2013232733A1 (en
Inventor
Alex LOUKAS
Severine NAVARRO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
James Cook University
Original Assignee
James Cook University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012900999A external-priority patent/AU2012900999A0/en
Application filed by James Cook University filed Critical James Cook University
Priority to AU2013232733A priority Critical patent/AU2013232733B2/en
Publication of AU2013232733A1 publication Critical patent/AU2013232733A1/en
Application granted granted Critical
Publication of AU2013232733B2 publication Critical patent/AU2013232733B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
AU2013232733A 2012-03-13 2013-03-13 Method for treating inflammation Active AU2013232733B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013232733A AU2013232733B2 (en) 2012-03-13 2013-03-13 Method for treating inflammation

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2012900999 2012-03-13
AU2012900999A AU2012900999A0 (en) 2012-03-13 Method for treating inflammation
PCT/AU2013/000247 WO2013134822A1 (en) 2012-03-13 2013-03-13 Method for treating inflammation
AU2013232733A AU2013232733B2 (en) 2012-03-13 2013-03-13 Method for treating inflammation

Publications (2)

Publication Number Publication Date
AU2013232733A1 AU2013232733A1 (en) 2014-10-09
AU2013232733B2 true AU2013232733B2 (en) 2017-01-19

Family

ID=49160149

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013232733A Active AU2013232733B2 (en) 2012-03-13 2013-03-13 Method for treating inflammation

Country Status (9)

Country Link
US (1) US9637527B2 (enExample)
EP (1) EP2849778B1 (enExample)
JP (1) JP6144288B2 (enExample)
CN (1) CN104411325B (enExample)
AU (1) AU2013232733B2 (enExample)
CA (1) CA2866819C (enExample)
ES (1) ES2664237T3 (enExample)
NZ (1) NZ629964A (enExample)
WO (1) WO2013134822A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105745223A (zh) 2013-09-18 2016-07-06 詹姆斯库克大学 修饰的抗炎蛋白及使用方法
AU2014324093A1 (en) * 2013-09-18 2016-04-28 James Cook University Anti-inflammatory proteins and methods of use
US10758568B2 (en) 2014-04-16 2020-09-01 Genovie Ab Regulatory T-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
WO2015158856A1 (en) 2014-04-16 2015-10-22 Genovie Ab Cd8+ regulatory t-cells for use in the treatment of inflammatory disorders of the human gastrointestinal tract
CN105561030A (zh) * 2015-09-18 2016-05-11 范月辉 一种治疗急性乳突炎的中药

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042232A1 (en) * 2001-10-17 2005-02-24 Peter Hotez Hookworm vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164225B (it) 1983-05-13 1987-04-08 Anic Spa Analoghi retro-invertiti del pentapeptide potenziante la bradichina bpp5a e metodi per la loro preparazione
US5284760A (en) 1989-04-03 1994-02-08 Feinstone Stephen M Techniques for producing site-directed mutagenesis of cloned DNA
US6090790A (en) 1989-12-14 2000-07-18 Eriksson; Elof Gene delivery by microneedle injection
US5220007A (en) 1990-02-15 1993-06-15 The Worcester Foundation For Experimental Biology Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
DE69233035D1 (de) 1991-12-24 2003-06-05 Harvard College Gezielte punkt-mutagenese von dna
US6756211B1 (en) * 1992-05-11 2004-06-29 Corvas International, Inc. Neutropohil inhibitors
US5389514A (en) 1992-08-28 1995-02-14 Fox Chase Cancer Center Method for specifically altering the nucleotide sequence of RNA
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AUPM672594A0 (en) 1994-07-08 1994-08-04 Royal Children's Hospital Research Foundation A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders
US5789166A (en) 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
WO1999047070A1 (en) 1998-03-18 1999-09-23 Wake Forest University Improved implantable biomaterials, compositions and methods for their preparation and uses thereof
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042232A1 (en) * 2001-10-17 2005-02-24 Peter Hotez Hookworm vaccine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHAN, B., et al., "Molecular cloning and characterization of Ac-TMP-2, a tissue inhibitor of metalloproteinase secreted by adult Ancylostoma caninum", Molecular & Biochemical Parasitology, 2008, Volume 162, Number 2, Page 142-148 *

Also Published As

Publication number Publication date
JP6144288B2 (ja) 2017-06-07
JP2015511588A (ja) 2015-04-20
EP2849778A4 (en) 2015-12-02
AU2013232733A1 (en) 2014-10-09
US9637527B2 (en) 2017-05-02
ES2664237T3 (es) 2018-04-18
CA2866819A1 (en) 2013-09-19
CN104411325B (zh) 2017-06-06
WO2013134822A1 (en) 2013-09-19
US20150037366A1 (en) 2015-02-05
NZ629964A (en) 2016-09-30
EP2849778A1 (en) 2015-03-25
CN104411325A (zh) 2015-03-11
CA2866819C (en) 2022-01-04
EP2849778B1 (en) 2017-12-27

Similar Documents

Publication Publication Date Title
EP2849778B1 (en) Ac-TMP-2 FOR USE IN TREATING INFLAMMATION
Monach et al. The role of antibodies in mouse models of rheumatoid arthritis, and relevance to human disease
CN106456723B (zh) 采用精氨酸酶i调节免疫系统的方法和组合物
US20110104156A1 (en) Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
WO2013160865A1 (en) Immunotolerizing fusion proteins for treatment of multiple sclerosis
Kurup et al. Animal models of allergic bronchopulmonary aspergillosis
Gubernatorova et al. Mouse models of severe asthma for evaluation of therapeutic cytokine targeting
US12466873B2 (en) Modified anti-inflammatory proteins and method of use
US20230192808A1 (en) Hla engineering methods and compositions for treatment of autoimmunity
Arnaboldi et al. Suppression of Th1 and Th17, but not Th2, responses in a CD8+ T cell-mediated model of oral tolerance
Varga et al. Immunomodulatory treatment strategies for allergic diseases
Hamasaka et al. DNA vaccination against macrophage migration inhibitory factor improves atopic dermatitis in murine models
CA2548502A1 (en) Methods and compositions relating to ccr5 antagonist, ifn-.gamma. and il-13 induced inflammation
WO2006088997A2 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin
JP2016536343A (ja) 抗炎症性のタンパク質及び使用方法
Guan Targeting IL-12 and/or IL-23 by employing peptide-based vaccines in the amelioration of murine colitis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)